Evaluation of endocervical glandular lesions using a scoring system and immunostain using p16&Ki67 antibodies.

Evaluation of endocervical glandular lesions using a scoring system and immunostain using p16&Ki67 antibodies. - Scoring system and immunostain

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000025210

Enrollment

100

Registered

2016-12-12

Start date

2016-12-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

noninvasitve endocervical glandular lesion

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Cytodiagnosis was patient with atypical grandular cell (AGC) or adenocarcinoma in situ; or patient with grandular dysplasia or adenocarcinoma in situ by biopsy.

Exclusion criteria

Exclusion criteria: A minor or the patients who are hard to declare their intentions.

Design outcomes

Primary

Measure	Time frame
Accuracy of scoring system	—

Secondary

Measure	Time frame
Expression of p16&Ki67 antibodies	—

Countries

Japan

Contacts

Public ContactSatoshi Okamoto

Tohoku university hospital gynecology

s-okamoto@med.tohoku.ac.jp022-717-7254

Outcome results